V600E/K mutations of the Raf family member BRAF are frequently found in melanoma and other solid tumor types for which the MAPK blocking agents dabrafenib and trametinib, inhibitors of BRAF and Mek, respectively, are used clinically in combination. This evidence concerns the gene BRAF and melanoma.